Back to today’s briefing

Story perspectives

Biotech Boom: Nasdaq Soars 15% Amid New Trials

5/5/2025

50 4

Summary

Story summary

Biotech companies are bouncing back with renewed vigor as the FDA finds its footing under new chief Marty Makary. The Nasdaq biotech index has surged 15% since April, fueled by exciting fast-track designations for Alterity and Immutep's groundbreaking cancer trials. However, Imugene struggles with a sharp drop in share prices amid concerns over its slower trial progress.

1 of 1

Story summary

Biotech companies are bouncing back with renewed vigor as the FDA finds its footing under new chief Marty Makary. The Nasdaq biotech index has surged 15% since April, fueled by exciting fast-track designations for Alterity and Immutep's groundbreaking cancer trials. However, Imugene struggles with a sharp drop in share prices amid concerns over its slower trial progress.